Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Secondary pneumonia MESHD pneumonia HP in critically ill ventilated patients with COVID-19

    Authors: Mailis Maes; Ellen Higginson; Joana Pereira Dias; Martin D Curran; Surendra Parmar; Fahad Khokhar; Delphine Cuchet-Lourenço; Janine Lux; Sapna Sharma-Hajela; Benjamin Ravenhill; Razeen Mahroof; Amelia Solderholm; Sally Forrest; Sushmita Sridhar; Nicholas M Brown; Stephen Baker; Vilas Navapurkar; Gordon Dougan; Josefin Bartholdson Scott; Andrew Conway Morris

    doi:10.1101/2020.06.26.20139873 Date: 2020-06-28 Source: medRxiv

    Background Pandemic COVID-19 caused by the coronavirus SARS-CoV-2 has a high incidence of patients with severe acute respiratory syndrome MESHD (SARS). Many of these patients require admission to an intensive care unit (ICU) for invasive artificial ventilation and are at significant risk of developing a secondary, ventilator-associated pneumonia MESHD pneumonia HP (VAP). Objectives To study the incidence of VAP, as well as differences in secondary infections, and bacterial MESHD lung microbiome composition of ventilated COVID-19 and non-COVID-19 patients. Methods In this prospective observational study, we compared the incidence of VAP and secondary infections MESHD using a combination of a TaqMan multi-pathogen array and microbial culture. In addition, we determined the lung microbime composition using 16S RNA analyisis. The study involved eighteen COVID-19 and seven non-COVID-19 patients receiving invasive ventilation in three ICUs located in a single University teaching hospital between April 13th 2020 and May 7th 2020. Results We observed a higher percentage of confirmed VAP in COVID-19 patients. However, there was no statistical difference in the detected organisms or pulmonary microbiome when compared to non-COVID-19 patients. Conclusion COVID-19 makes people more susceptible to developing VAP, partly but not entirely due to the increased duration of ventilation. The pulmonary dysbiosis MESHD caused by COVID-19, and the array of secondary infections MESHD observed are similar to that seen in critically ill patients ventilated for other reasons.

    Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure HP in COVID-19

    Authors: Maulin Patel; Andrew Gangemi; Robert Marron; Junad Chowdhury; Ibraheem Yousef; Matthew Zheng; Nicole Mills; Lauren Tragesser; Julie Giurintano; Rohit Gupta; Matthew Gordon; Parth Rali; David Fleece; Huaqing Zhao; Nicole Patlakh; Gerard J Criner

    doi:10.1101/2020.05.22.20109355 Date: 2020-05-26 Source: medRxiv

    Abstract Invasive mechanical has been associated with high mortality in COVID-19. Alternative therapy of High flow nasal therapy (HFNT) has been greatly debated around the world for use in COVID-19 pandemic due to concern for increased healthcare worker transmission TRANS. Methods This was a retrospective analysis of consecutive patients admitted to Temple University Hospital in Philadelphia, Pennsylvania, from March 10, 2020, to April 24, 2020 with moderate to severe respiratory failure HP treated with High Flow nasal therapy (HFNT). Primary outcome was prevention of intubation. Results Of the 445 patients with COVID-19, 104 met our inclusion criteria. The average age TRANS was 60.66 (+13.50) years, 49 (47.12 %) were female TRANS, 53 (50.96%) were African American, 23 (22.12%) Hispanic. Forty-three patients (43.43%) were smokers. SF and chest Xray scores had a statistically significant improvement from day 1 to day 7. 67 of 104 (64.42%) were able to avoid invasive mechanical ventilation in our cohort. Incidence of hospital/ ventilator associated pneumonia MESHD pneumonia HP was 2.9%. Overall, mortality was 14.44% (n=15) in our cohort with 13 (34.4%) in the progressed to intubation group and 2 (2.9%) in the non-intubation group. Mortality and incidence of VAP/HAP was statistically higher in the progressed to intubation group. Conclusion HFNT use is associated with a reduction in the rate of Invasive mechanical ventilation and overall mortality in patients with COVID-19 infection MESHD.

    Analysis of oral risk-factors for ventilator-associated pneumonia MESHD pneumonia HP in critically ill patients

    Authors: Ademar Takahama Jr; Vitoria Iaros de Sousa; Elisa Emi Tanaka; Evelise Ono; Fernanda Akemi Nakanishi Ito; Priscila Paganini Costa; Maria Beatriz Bergonse Pedrialli; Heliton Gustavo de Lima; Marco Aurélio Fornazieri; Leticia Sassaki Correia; Lucienne Tibery Queiroz Cardoso; Claudia Maria Dantas de Maio Carrilho

    doi:10.21203/ Date: 2020-04-17 Source: ResearchSquare

    Objective: This a cross-sectional study to evaluate the association between oral health findings and ventilator-associated pneumonia MESHD pneumonia HP (VAP) among critically ill patients in intensive care units (ICU). Material and Methods: Data were collected from medical records, and a detailed oral physical examination was performed on 663 critically ill patients on mechanical ventilation. Data were statistically analysed using univariate and logistic regression models relating the development of VAP with the oral findings. Results: At oral physical examination, the most frequent findings were tooth loss MESHD (568 - 85.67%), coated tongue (422 - 63.65%) and oral bleeding HP (192 - 28.96%). Patients with a coated tongue or oral bleeding HP on the first day of ICU hospitalization developed more VAP than did patients without these conditions (20.14% vs 13.69%: p=0.02; 23.44% vs 15.50%: p=0.01, respectively). In the logistic regression, a coated tongue and oral bleeding HP were considered independent risk factors for VAP development [OR=1.60 (1.02-2.47) and OR=1.59 (1.05 – 2.44), respectively]. Conclusions: The presence of a coated tongue and oral bleeding HP in ICU admission could be considered markers for the development of VAP. Clinical relevance: The results of this paper reinforces the importance of proper maintenance of oral hygiene before intubation, which may lead to a decrease in the incidence of VAP in the ICU. This is particularly important in the COVID-19 current scenario, where more people are expected to need mechanical ventilation, consequently increasing cases of VAP.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.